In particular, IL-6 has emerged as a candidate biomarker because of its central role in COVID-19 pathophysiology, its strong association with disease severity, and its use for risk stratification and eligibility for IL-6–targeted drugs [4,5,6]. Here, IL6 is linked to COVID-19.